SCHEDULE: Commodore Capital Discloses 5.5% Stake in Cogent

Commodore Capital and its affiliates have reported a 5.5% passive ownership stake in Cogent Biosciences, Inc., totaling 6,408,060 shares.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively reported beneficial ownership of 6,408,060 shares of Cogent Biosciences, Inc. Common Stock.
• This represents a 5.5% ownership stake in the company.
• The ownership includes 3,450,000 shares of common stock, 2,352,000 shares underlying Series B Non-Voting Convertible Preferred Stock, and 606,060 shares underlying a warrant.
• The convertible preferred stock and warrants are subject to a beneficial ownership limitation of 9.99%.
• The ownership percentage is calculated based on 113,928,492 common shares reported as issued and outstanding as of June 30, 2025, in Cogent Biosciences' Quarterly Report on Form 10-Q, plus the shares underlying the convertible preferred stock and warrants.
• The investment is explicitly stated as passive, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: A significant passive stake by a reputable investment firm generally signals positive investor confidence in the company's long-term prospects, although it does not imply active management involvement.

Positives

• A notable investment firm, Commodore Capital, has taken a significant 5.5% stake, indicating confidence in Cogent Biosciences' long-term prospects.
• The investment includes convertible preferred stock and warrants, suggesting a potential for increased equity participation and a long-term view from the investor.

Negatives

• No specific negative financial or operational details were disclosed in this ownership filing.

Risks

• The investment is stated as not being for the purpose of changing or influencing control of the issuer, which means the investor will not actively drive strategic changes.

Future Outlook

The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of Cogent Biosciences, Inc., indicating a passive investment strategy.

Management Comments

• No direct management comments from Cogent Biosciences, Inc. were included in this filing.

Industry Context

This filing indicates a significant passive investment in a biotechnology company, which is common for institutional investors seeking exposure to the sector's growth potential.

Comparison to Industry Standards

• No specific financial or operational results are presented in this ownership filing to allow for direct comparison to industry standards or specific comparable companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 5.5% stake may instill confidence and potentially attract other investors, positively impacting share price stability.
• Management: Management may view this as a vote of confidence, but the passive nature of the investment means no immediate pressure for strategic changes from this specific investor.

Next Steps

• The reporting persons will continue to hold their passive investment in Cogent Biosciences, Inc.

Key Dates

Recommendation

The filing indicates a significant passive investment by Commodore Capital, signaling institutional confidence in Cogent Biosciences. While this is a positive indicator, the filing itself does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a stronger recommendation. The investment is explicitly stated as not being for control, suggesting a long-term, non-interventional holding.

Keywords

Cogent Biosciences, Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Commodore Capital, Biotechnology, Pharmaceutical